Clinicopathological features of breast cancer in Japanese female patients with Lynch syndrome. 2019

Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
Department of Surgery, Iwakuni Clinical Center, Yamaguchi, Japan. nov19841026@okayama-u.ac.jp.

BACKGROUND Lynch syndrome (LS) is a predominantly inherited syndrome caused by a pathological germline mutation in one of the mismatch repair (MMR) genes. Whether breast cancer (BC) is one of the LS-associated tumors is controversial. The aim of this retrospective cohort study was to evaluate the clinical features of BC in Japanese patients with LS. METHODS Of 38 mutation carriers, 4 females with BC were examined in this study. RESULTS Two of the four patients had multiple BC. Their median age at the diagnosis of BC was 63 (range, 47-84) years. The TNM (6th revision) stages of the six BCs were as follows: stage I, 33% (2/6); stage IIA, 50% (3/6); and stage IIB, 17% (1/6). Histological examination revealed four scirrhous, one papillotubular, and one medullary carcinoma. The positive ratios for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth receptor 2 (HER2) were 83.3% (5/6), 83.3% (5/6), and 16.7% (1/6), respectively. Two of the three specimens showed MSI-H and one showed MSS. These MSI-H BCs had tumor-infiltrating lymphocytes. Two of the three specimens showed an absence of MLH1 and PMS2 proteins on immunohistochemistry. The cumulative risks for a person with LS to develop BC were 4.35% at the age of 50 years, 8.70% at 60 years, and 21.5% at 70 years. CONCLUSIONS Our study results showed BC in Japanese females with LS to be an MSI-H tumor, which was ER and PgR positive and HER2 negative.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003123 Colorectal Neoplasms, Hereditary Nonpolyposis A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer. Colon Cancer, Familial Nonpolyposis, Type 1,Colorectal Cancer, Hereditary Nonpolyposis, Type 1,Familial Nonpolyposis Colon Cancer Type 1,Hereditary Nonpolyposis Colorectal Cancer,Hereditary Nonpolyposis Colorectal Cancer Type 1,Hereditary Nonpolyposis Colorectal Neoplasms,Lynch Syndrome,Colon Cancer, Familial Nonpolyposis,Colorectal Cancer Hereditary Nonpolyposis,Familial Nonpolyposis Colon Cancer,Hereditary Nonpolyposis Colon Cancer,Lynch Cancer Family Syndrome I,Lynch Syndrome I,Syndrome, Lynch
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
January 2012, Pathology research international,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
May 2009, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
February 2023, Breast cancer research and treatment,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
January 2021, Asia-Pacific journal of oncology nursing,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
November 2014, Breast cancer (Tokyo, Japan),
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
December 2022, Cancers,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
November 2015, Human pathology,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
January 2018, PloS one,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
January 2010, Molecular medicine reports,
Nobuhiko Kanaya, and Kohji Tanakaya, and Rie Yamasaki, and Takashi Arata, and Kunitoshi Shigeyasu, and Hideki Aoki, and Toshiaki Morito, and Hiromi Sanaii, and Kiwamu Akagi, and Toshiyoshi Fujiwara
November 2022, Pediatric blood & cancer,
Copied contents to your clipboard!